Clinical Trials Logo

Recurrent Urinary Tract Infections clinical trials

View clinical trials related to Recurrent Urinary Tract Infections.

Filter by:
  • None
  • Page 1

NCT ID: NCT02869165 Recruiting - Menopause Clinical Trials

Vaginal and Urinary Microbiome Trial

Start date: January 2017
Phase: Phase 4
Study type: Interventional

A randomized controlled trial looking at the effects of vaginal estrogen and a nonhormonal alternative on the vaginal and urinary microbiome in women with genitourinary syndrome of menopause.

NCT ID: NCT02490046 Recruiting - Multiple Sclerosis Clinical Trials

D-mannose for the Prevention of UTIs in Multiple Sclerosis

Start date: February 2015
Phase: Phase 1
Study type: Interventional

This is a study to explore the feasibility of using D-mannose, a commonly used food supplement, in persons with multiple sclerosis reporting recurrent urinary tract infections. Twenty persons with multiple sclerosis (10 patients using catheters and 10 not using catheters) reporting recurrent urinary tract infections will receive D-mannose 1.5 grams twice daily for 16 weeks duration. This will be explored through: 1. Assessing compliance to a 16-week course of D-mannose 2. Quantifying the number of prescriptions for antibiotics during the 16 weeks course of D-mannose

NCT ID: NCT02246270 Withdrawn - Clinical trials for Recurrent Urinary Tract Infections

Recurrent Urinary Tract Infections and Heparin (RUTIH Trial)

Start date: November 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Urinary Tract Infections (UTIs) are the second most common infection in the body. UTIs account for five percent of all visits to primary care physicians. Many women who have had a UTI will develop recurring urinary tract infections. Recent studies suggest that some women who suffer from recurrent UTIs have urinary tracts that allow bacteria to adhere to it more readily than others. Women who suffered from bladder inflammation and recurrent UTIs were noted to have reduced UTIs and bladder inflammation with heparin bladder instillations. Heparin is a highly-sulfated glycosaminoglycan and stored within the secretory granules of mast cells and released only into the vasculature at sites of tissue injury. It has been proposed that, in addition to anticoagulation, the main purpose of heparin is defense at such sites against invading bacteria and other foreign materials. The central question the research is intended to answer is does Heparin bladder instillations decrease UTI rates in patients.

NCT ID: NCT02016118 Recruiting - Clinical trials for Recurrent Urinary Tract Infections

Retrospective Analysis of Ialuril vs. Standard of Care in Recurrent Urinary Tract Infections

Start date: January 2014
Phase: N/A
Study type: Observational

The purpose of this study is to assess the effectiveness and costs associated with the intravesical administration of combined hyaluronic acid (HA) and chondroitin sulphate (CS) compared to the current standard management of recurrent urinary tract infections in adult women diagnosed with recurrent urinary tract infections (RUTI).

NCT ID: NCT01663181 Completed - Overactive Bladder Clinical Trials

Pain-perception During Outpatient cystoscopy-a Prospective Controlled Study

Start date: May 2009
Phase: N/A
Study type: Observational

At an academic tertiary referral center, patients with pelvic floor dysfunction, scheduled for outpatient cystoscopy or urodynamic testing will be asked to participate in the study. Patients will be called one day after the examination and will be asked about pain and their general state of health. The purpose of this study it to investigate pain perception in urogynecologic patients during outpatient cystoscopy and compare it with pain perception during outpatient urodynamic. The investigators will also investigate the difference between anticipated and actual pain perception. The investigators will test the null hypothesis that there is no difference in patients´ pain perception between outpatient cystoscopy and urodynamic testing. The secondary hypothesis will be that there is no difference between patients´ anticipated amount of pain and the actually experienced pain during cystoscopy and urodynamic testing. According to power calculation, a sample size of 52 patients per group will be needed to detect a 2 cm difference in pain scores on the VAS - judged as a clinically significant difference - with 95% power and a two-sided significance level of 0.05. Exclusion criteria are: age ≤ 18 years, insufficient ability to understand German, pregnancy and the participation in another clinical study at the same time.

NCT ID: NCT00678028 Completed - Clinical trials for Recurrent Urinary Tract Infections

Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection

Start date: February 2008
Phase: N/A
Study type: Observational

Due to genetic polymorphism about 15%-30% of the world population have low levels of MBL (Mannose Binding Lectin) in serum (below 500ng/mL). Different studies reported correlation between polymorphism in the MBL gene with low levels of MBL in serum and higher frequency of recurrent infections, severity of sepsis, ARDS and other infections. Urinary Tract Infection (UTI) is one of the very common infection in women. Since MBL is part of the innate immunity and there are proofs of relation between patients with recurrent infections and lack of MBL, we decided to explore a possible relation between low levels of MBL and different genotypes of MBL in young women and the risk to develop recurrent UTI.